In recent years, numerous studies using NLRP3 inflammasome-related drugs and inhibitors in experimental models have supported the therapeutic approach for treating NAFLD/NASH, demonstrating positive effects. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.